NLRP3 and acute respiratory distress syndrome: Several pharmacological agents and natural compounds have been shown to modulate NLRP3 inflammasome activation and hold promise as potential therapeutics for ALI (Ozaki et al., 2015; Das et al., 2021; Wang et al., 2022).